Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

Welltower Inc.

WELL
Real Estate · REIT - Healthcare Facilities

Welltower Inc. is coiled. The quarters are improving, yet the P/E sits at the 35th percentile of its own 5-year range — the business is moving before the market.

The sharpest disagreement: the price moved +42.0% in a year while annual EPS moved −11.5% — the difference is re-rating, and re-rating has to be repaid with earnings.

The price is in a confirmed uptrend (158 weeks in) while the P/E sits at the 35th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +53.3% year on year, and 294% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.

Stage
Mixed
fundamental trajectory, 12 quarters
Price
$235
+42.0% 1Y
P/E
106.3×
35th pctile
of its own 5-year range
Revenue (Jun 26)
$3.5 B
+38.8% YoY
Profit (Jun 26)
$0.5 B
+53.3% YoY
Operating margin
14.1%
−3.2 pp YoY
ROE
4%
FY25
ROIC
1.3%
vs WACC 7.9% → −6.6 pp
Cash conversion
294%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Welltower Inc. trades at $235, in a confirmed uptrend and 158 weeks into that stage. That is +10.6% against its own 200-day average. It sits at 80% of a 52-week range of $166 to $252. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 13 straight weeks.

Today the stock is in a confirmed uptrend — week 158 of stage 2. At $235 it trades +10.6% versus its 200-day average and sits at 80% of its 52-week range ($166–$252).

Sep 26: $235 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+10.6% versus the 200-day line, week 158 of stage 2
Price50-day avg200-day avg
S2$266$215$164$113$61.7$$235$212Sep 23Jun 24Mar 25Dec 25Sep 26
S2$266$215$164$113$61.7$$235$212Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (533 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Sep 26

Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +210% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 13 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Welltower Inc. trades at 106.3× P/E, near the bottom of its own range — cheaper only 35% of the time. Its long-run median P/E is 120.7×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 106.3× is near the bottom of its own range — cheaper only 35% of the time, against a long-run median of 120.7× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 106.3× vs a 120.7× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.5-year window; loss-period spikes above 359× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 35% of the time
P/EMedianEPS (TTM) (quarterly)
381.8×$2.4299.4×$1.8217.0×$1.2134.6×$0.652.2×$0.0×$107.57×$2Apr 22May 23Jun 24Aug 25Sep 26
381.8×$2.4299.4×$1.8217.0×$1.2134.6×$0.652.2×$0.0×$107.57×$2Apr 22Jun 24Sep 26
PEG 4.49 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Computed here as quarter-end P/E ÷ trailing-twelve-month EPS growth (only quarters with positive growth), because a reported quarterly PEG is not held for this stock. Last 10 quarters; values above 6 pinned at the top.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
6.5×4.8×3.2×1.6×0.0××4.49×Sep 23Mar 24Sep 24Mar 25Jun 26
6.5×4.8×3.2×1.6×0.0××4.49×Sep 23Sep 24Jun 26
P/E
106.3×
35th percentile of 5y
PEG
5.63
as reported

🚨 Why the multiple sits where it does: over the past year annual EPS moved −11.5% against a +42.0% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the +40.6%/yr price move, ~+111.6%/yr came from earnings growth and ~−71.0 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Welltower Inc. reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 0.8% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +35.7% in FY25, profit −1.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
37%188%31%120%25%52%18%−16%12%−85%%%35.7%−1%FY21FY23FY25
37%188%31%120%25%52%18%−16%12%−85%%%35.7%−1%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating, profit rolling over
RevenueProfitEPS
40%325%33%235%26%145%18%55%11%−35%%%37.5%41.2%23.2%Sep 23Dec 24Jun 26
40%325%33%235%26%145%18%55%11%−35%%%37.5%41.2%23.2%Sep 23Dec 24Jun 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
3.1%2.4%1.7%0.9%0.2%%0.8%Sep 23Mar 24Dec 24Sep 25Jun 26
3.1%2.4%1.7%0.9%0.2%%0.8%Sep 23Dec 24Jun 26
Revenue growth
Steady high
latest +37.5% · span +13.3% to +37.7%
Profit growth
Rising
latest +41.2% · span −1.0% to +335.7%
EPS growth
Rising
latest +23.2% · span −10.3% to +347.8%
ROCE
Stuck low
latest 0.8% · span 0.4%–2.9%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+35.7%+22.8%
Profit−1.0%+81.7%
EPS−11.5%+66.7%
Stock price+42.0%+40.6%+22.3%+12.3%
Revenue YoY (Jun 26)
+38.8%
latest quarter vs a year ago
Profit YoY (Jun 26)
+53.3%
latest quarter vs a year ago
Revenue 10y
23.0%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

57.0/100 — rank 3 of 17 in REIT - Healthcare Facilities · 80% evidence confidence

Welltower Inc. scores 57.0 out of 100 against the 17 companies it is compared with in REIT - Healthcare Facilities, ranking 3. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 24.4 + 10.9 + 4.3 + 17.4 = 57. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Welltower Inc. reported $3.5 B of revenue in the Jun 26 quarter, +38.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 23.0% a year. The last full year, FY25, came in at $10.8 B. The last four reported quarters add to $12.8 B.

FY25 revenue came in at $10.8 B (+35.7% on the year), capping 4 years at 23.0% compound. The latest quarter (Jun 26) printed $3.5 B, +38.8% year on year — the 12th consecutive quarter of year-over-year growth.

FY25 revenue $10.8 B (+35.7% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
23.0% a year over 4 years
RevenueYoY growth
1237%8.831%5.925%2.918%0.012%$ B%$11B35.7%FY21FY23FY25
1237%8.831%5.925%2.918%0.012%$ B%$11B35.7%FY21FY23FY25
Jun 26: $3.5 B (+38.8% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
3.844%2.935%1.925%1.016%0.06.4%$ B%$4B38.8%Sep 23Dec 24Jun 26
3.844%2.935%1.925%1.016%0.06.4%$ B%$4B38.8%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +37.3% growth against the decade's 23.0% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +37.5% over the last 4 quarters against +34.2%/yr over the last 8 — accelerating; TTM profit +41.2% vs +62.5%/yr — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Welltower Inc.'s operating margin is 14.1% in the Jun 26 quarter, −3.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.8% to 14.8%. The current quarter sits inside that band.

The latest quarter's operating margin is 14.1%, −3.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.8%–14.8%.

🚨 Why the margin moved: operating margin went −3.2 pp year on year while gross margin went −1.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 1.8% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 1.8–14.8% band over 5 years
operating marginYoY change (pp)
16%3.5%12%−0.5%8.3%−4.6%4.5%−8.7%0.8%−13%%%1.8%−11.6%FY21FY23FY25
16%3.5%12%−0.5%8.3%−4.6%4.5%−8.7%0.8%−13%%%1.8%−11.6%FY21FY23FY25
Jun 26: 14.1% operating margin (−3.2 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
22%9.2%7.3%−5.3%−7.7%−20%−23%−34%−38%−49%%%14.1%−3.2%Sep 23Dec 24Jun 26
22%9.2%7.3%−5.3%−7.7%−20%−23%−34%−38%−49%%%14.1%−3.2%Sep 23Dec 24Jun 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Welltower Inc. earned $0.5 B of net profit in the Jun 26 quarter, +53.3% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $1.0 B. The 4-year compound rate is 26.9%. That is 13.0% of the quarter's revenue. The same quarter a year earlier earned $0.3 B.

Jun 26 profit was $0.5 B, +53.3% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $1.0 B (−1.0%), and the 4-year compound rate is 26.9%.

FY25 profit $1.0 B (−1.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
26.9% a year over 4 years
Net profitYoY growth
1.0187%0.8122%0.556%0.3−9.3%0.0−75%$ B%$1B−1%FY21FY23FY25
1.0187%0.8122%0.556%0.3−9.3%0.0−75%$ B%$1B−1%FY21FY23FY25
Jun 26: $0.5 B (+53.3% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Net profit (quarterly)YoY growth
0.8363%0.6255%0.4147%0.239%0.0−69%$ B%$1B53.3%Sep 23Dec 24Jun 26
0.8363%0.6255%0.4147%0.239%0.0−69%$ B%$1B53.3%Sep 23Dec 24Jun 26

Why profit moved: revenue contributed +38.8% and the margin −3.2 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +50.7% vs revenue +37.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 294% of Welltower Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $2.9 B of operating cash against $1.0 B of profit. After $1.5 B of capital spending, $1.4 B was left as free cash.

FY25: operating cash of $2.9 B against reported profit of $1.0 B, leaving free cash of $1.4 B after $1.5 B of capital spending. Across the last 3 fiscal years the conversion rate is 294% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $2.9 B vs profit $1.0 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
294% of 3-year profit arrived as cash
Operating cashNet profitFree cash
3.12.31.60.80.0$ B$3B$1B$1BFY21FY23FY25
3.12.31.60.80.0$ B$3B$1B$1BFY21FY23FY25
Jun 26: operating cash $1.0 B = 217% of the quarter's profit Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
1.1578%0.8447%0.5316%0.3184%0.053%$ B%$1B217%Sep 23Dec 24Jun 26
1.1578%0.8447%0.5316%0.3184%0.053%$ B%$1B217%Sep 23Dec 24Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Welltower Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $5.0 B over the last 3 years. Averaged over those years that is 15.4% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $5.0 B over the last 3 fiscal years.

FY25: capex $1.5 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
1.91.40.90.50.0$ B$2BFY21FY23FY25
1.91.40.90.50.0$ B$2BFY21FY23FY25
Jun 26: capex $0.4 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.60.70.40.50.30.30.10.00.0−0.2$ B$ B$0B$1BSep 23Dec 24Jun 26
0.60.70.40.50.30.30.10.00.0−0.2$ B$ B$0B$1BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Welltower Inc. earns a ROE of 2% in FY25. That is up from a trough of 1% in FY22. Return on invested capital clears the cost of that capital by −6.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 8.9% net margin on 0.16× asset turns.

FY25 ROE is 2%, recovered from a FY22 trough of 1% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY25): 8.9% net margin × 0.16× asset turns × 1.56× balance-sheet leverage ≈ 2.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 1.3% − 7.9% = a −6.6 pp spread. The 7.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY25: ROE 2% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 7.9% cost of capital used on this page.
the climb back from FY22's 1%
ROEROIC (annual)WACC
8.5%6.3%4.2%2.0%−0.2%%2.2%0.4%FY21FY23FY25
8.5%6.3%4.2%2.0%−0.2%%2.2%0.4%FY21FY23FY25
Jun 26: ROIC 0.7% (TTM) vs WACC 7.9% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
8.5%6.3%4.1%1.9%−0.3%%0.7%1.1%Sep 23Dec 24Jun 26
8.5%6.3%4.1%1.9%−0.3%%0.7%1.1%Sep 23Dec 24Jun 26
11 · Dividend

Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.

Welltower Inc. paid $3.07 per share over the last four reported quarters. The most recent declaration was $0.85 for Jun 26. Against the current price of $235 that is a trailing yield of 1.31%, measured on dividends already paid rather than on a forecast.

Welltower Inc. paid $3.07 per share across the last four reported quarters, most recently $0.85 for Jun 26. Against the current price of $235 the trailing twelve months work out to 1.31% — trailing dividends measured against today's price, not a forward estimate.

Dividend per share by quarter Declared dividend per share, $ B, per reported quarter. 12 quarters on file.
latest $0.85 (Jun 26)
Dividend per share
0.90.70.50.20.0$ B$1BSep 23Mar 24Dec 24Sep 25Jun 26
0.90.70.50.20.0$ B$1BSep 23Dec 24Jun 26
12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Welltower Inc. carries total debt of $19.7 B against shareholder equity of $47.7 B as of Jun 26, a debt-to-equity of 0.41. On the annual view that ratio went from 0.77 in FY21 to 0.49 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of $19.7 B against shareholder equity of $47.7 B — a debt-to-equity of 0.41. On the annual view, debt-to-equity went from 0.77 (FY21) to 0.49 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $21.4 B at 0.49× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
230.79×170.71×120.63×5.80.55×0.00.47×$ B×$21B0.49×FY21FY23FY25
230.79×170.71×120.63×5.80.55×0.00.47×$ B×$21B0.49×FY21FY23FY25
Jun 26: debt $19.7 B, debt-to-equity 0.41 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
230.8×170.7×120.6×5.80.5×0.00.4×$ B×$20B0.41×Sep 23Dec 24Jun 26
230.8×170.7×120.6×5.80.5×0.00.4×$ B×$20B0.41×Sep 23Dec 24Jun 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

2.6% of Welltower Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 6.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 2.6% of the float is sold short, and at typical trading volumes it would take about 6.2 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
2.6%
of the tradable float
Days to cover
6.2
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Welltower Inc.: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

15 · Related companies · REIT - Healthcare Facilities
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1LTC Properties, Inc.LTC 68.3/100Favorable setup76% evidence BREAKING OUT 25.9/35 Income 53.3% · PAT 39.1% 71% evidence 15.6/25 ROA 1.8% · ROE 2.1% · GNPA — 68% evidence 7.6/20 P/BV 1.67× · P/BV÷ROE 0.79 70% evidence 19.2/20 RS sector 11.4% · RS bench 6.7% · 1Y 20.3%5 of 12 weeks ahead 100% evidence
Exact sum: 25.9 + 15.6 + 7.6 + 19.2 = 68.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Strawberry Fields REIT, Inc.STRW 58.4/100Mixed-positive evidence70% evidence BREAKING OUT 18.6/35 Income 26.4% · PAT 28.6% 71% evidence 20.4/25 ROA 2.6% · ROE 37.4% · GNPA — 68% evidence 7.8/20 P/BV 13.04× · P/BV÷ROE 0.35 70% evidence 11.6/20 RS sector 2.8% · RS bench -1.5% · 1Y 11.2%3 of 12 weeks ahead 70% evidence
Exact sum: 18.6 + 20.4 + 7.8 + 11.6 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Welltower Inc.this pageWELL 57.0/100Mixed-positive evidence80% evidence LEADER 24.4/35 Income 37.6% · PAT 41.3% 81% evidence 10.9/25 ROA 0.9% · ROE 1.1% · GNPA — 68% evidence 4.3/20 P/BV 3.52× · P/BV÷ROE 3.2 70% evidence 17.4/20 RS sector 11% · RS bench 6.3% · 1Y 42%9 of 12 weeks ahead 100% evidence
Exact sum: 24.4 + 10.9 + 4.3 + 17.4 = 57 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Omega Healthcare Investors, Inc.OHI 56.6/100Mixed-positive evidence60% evidence TURNING 20.3/35 Income — · PAT — 26% evidence 17.5/25 ROA 1.8% · ROE 7% · GNPA — 68% evidence 8.0/20 P/BV 2.65× · P/BV÷ROE 0.38 70% evidence 10.8/20 RS sector 0.4% · RS bench -3.9% · 1Y 13%1 of 12 weeks ahead 100% evidence
Exact sum: 20.3 + 17.5 + 8 + 10.8 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Ventas, Inc.VTR 52.0/100Mixed-positive evidence80% evidence BREAKING OUT 24.9/35 Income 21.6% · PAT 37.2% 81% evidence 10.2/25 ROA 1.1% · ROE 0.5% · GNPA — 68% evidence 3.4/20 P/BV 3.11× · P/BV÷ROE 6.22 70% evidence 13.5/20 RS sector 3.8% · RS bench -0.7% · 1Y 31.4%5 of 12 weeks ahead 100% evidence
Exact sum: 24.9 + 10.2 + 3.4 + 13.5 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6CareTrust REIT, Inc.CTRE 51.2/100Mixed-positive evidence76% evidence TURNING 22.8/35 Income 58.2% · PAT 100% 71% evidence 16.5/25 ROA 2% · ROE 2.2% · GNPA — 68% evidence 6.9/20 P/BV 2.01× · P/BV÷ROE 0.91 70% evidence 5.0/20 RS sector -3.1% · RS bench -7.3% · 1Y 10.6%1 of 12 weeks ahead 100% evidence
Exact sum: 22.8 + 16.5 + 6.9 + 5 = 51.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -3.1% and the one-year return is 10.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
7Universal Health Realty Income TrustUHT 49.1/100Mixed-negative evidence60% evidence TURNING 18.7/35 Income — · PAT — 26% evidence 15.9/25 ROA 1.6% · ROE 3.8% · GNPA — 68% evidence 5.5/20 P/BV 4.23× · P/BV÷ROE 1.11 70% evidence 9.0/20 RS sector -2.4% · RS bench -6.6% · 1Y -1.3%1 of 12 weeks ahead 100% evidence
Exact sum: 18.7 + 15.9 + 5.5 + 9 = 49.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8American Healthcare REIT, Inc.AHR 46.1/100Mixed-negative evidence67% evidence BREAKING OUT 17.7/35 Income 12.2% · PAT — 45% evidence 8.4/25 ROA 0.8% · ROE 0.8% · GNPA — 68% evidence 4.4/20 P/BV 2.57× · P/BV÷ROE 3.22 70% evidence 15.6/20 RS sector 4.6% · RS bench 0.1% · 1Y 25.9%9 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 8.4 + 4.4 + 15.6 = 46.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Sabra Health Care REIT, Inc.SBRA 45.8/100Mixed-negative evidence76% evidence TURNING 16.8/35 Income 12.9% · PAT 11.3% 71% evidence 11.7/25 ROA 1.1% · ROE 1.5% · GNPA — 68% evidence 5.9/20 P/BV 1.74× · P/BV÷ROE 1.16 70% evidence 11.4/20 RS sector 0% · RS bench -4.2% · 1Y 7.4%4 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 11.7 + 5.9 + 11.4 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Diversified Healthcare TrustDHC 43.9/100Thin evidence · provisional55% evidence ASLEEP 15.8/35 Income 0.4% · PAT — 45% evidence 4.3/25 ROA -0.1% · ROE -2.4% · GNPA — 68% evidence 9.8/20 P/BV 0.99× · P/BV÷ROE — 10% evidence 14.0/20 RS sector 16.1% · RS bench 10.7% · 1Y 73.4%5 of 12 weeks ahead 100% evidence
Exact sum: 15.8 + 4.3 + 9.8 + 14 = 43.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11Healthpeak Properties, Inc.DOC 42.6/100Mixed-negative evidence76% evidence FADING 10.1/35 Income 2.7% · PAT -18.2% 71% evidence 9.4/25 ROA 0.4% · ROE 2.2% · GNPA — 68% evidence 7.9/20 P/BV 1.46× · P/BV÷ROE 0.66 70% evidence 15.2/20 RS sector 6.9% · RS bench 2.4% · 1Y 10.2%7 of 12 weeks ahead 100% evidence
Exact sum: 10.1 + 9.4 + 7.9 + 15.2 = 42.6 · Decision use: Price leads the evidence: RS versus the benchmark is 2.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
12National Health Investors, Inc.NHI 42.5/100Mixed-negative evidence76% evidence BASING 16.6/35 Income 17.2% · PAT 5% 71% evidence 16.8/25 ROA 1.8% · ROE 2.7% · GNPA — 68% evidence 6.4/20 P/BV 2.59× · P/BV÷ROE 0.96 70% evidence 2.7/20 RS sector -14.6% · RS bench -18.3% · 1Y -13.2%0 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 16.8 + 6.4 + 2.7 = 42.5 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
13Sila Realty Trust, Inc.SILA 41.7/100Mixed-negative evidence70% evidence 14.9/35 Income 9.7% · PAT -71.4% 71% evidence 9.2/25 ROA 1% · ROE 0.3% · GNPA — 68% evidence 4.1/20 P/BV 0.98× · P/BV÷ROE 3.27 70% evidence 13.5/20 RS sector 2.8% · RS bench 8.8% · 1Y 26.4%1 of 1 week ahead to 2026-07-02 70% evidence
Exact sum: 14.9 + 9.2 + 4.1 + 13.5 = 41.7 · Decision use: Price leads the evidence: RS versus the benchmark is 8.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
14Community Healthcare Trust IncorporatedCHCT 35.2/100Mixed-negative evidence61% evidence BASING 16.2/35 Income 5.1% · PAT — 45% evidence 9.4/25 ROA 0.9% · ROE 0.6% · GNPA — 68% evidence 5.5/20 P/BV 1.08× · P/BV÷ROE 1.8 70% evidence 4.1/20 RS sector -12.2% · RS bench -16.1% · 1Y -2.4%1 of 12 weeks ahead 70% evidence
Exact sum: 16.2 + 9.4 + 5.5 + 4.1 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Chiron Real Estate Inc.XRN 30.5/100Adverse evidence70% evidence TURNING 9.7/35 Income 9.4% · PAT -200% 71% evidence 7.5/25 ROA 0.7% · ROE 0.3% · GNPA — 68% evidence 5.2/20 P/BV 0.88× · P/BV÷ROE 2.92 70% evidence 8.1/20 RS sector -0.1% · RS bench -4.3% · 1Y -5.4%1 of 12 weeks ahead 70% evidence
Exact sum: 9.7 + 7.5 + 5.2 + 8.1 = 30.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Medical Properties Trust, Inc.MPT 27.6/100Adverse evidence67% evidence ASLEEP 14.3/35 Income 5.4% · PAT — 45% evidence 5.8/25 ROA -93.4% · ROE 0.7% · GNPA — 68% evidence 7.2/20 P/BV 0.61× · P/BV÷ROE 0.87 70% evidence 0.3/20 RS sector -33.1% · RS bench -35.9% · 1Y -32.3%0 of 12 weeks ahead 100% evidence
Exact sum: 14.3 + 5.8 + 7.2 + 0.3 = 27.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Healthcare Realty Trust IncorporatedHR 39.0/100Thin evidence · provisional48% evidence ASLEEP 20.4/35 Income — · PAT — 26% evidence 5.2/25 ROA 0.4% · ROE -1% · GNPA — 68% evidence 9.8/20 P/BV 1.64× · P/BV÷ROE — 10% evidence 3.6/20 RS sector -2.8% · RS bench -6.9% · 1Y 2.3%4 of 12 weeks ahead 100% evidence
Exact sum: 20.4 + 5.2 + 9.8 + 3.6 = 39 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Welltower Inc.'s stock price today?

Welltower Inc. trades at $235, +42.0% over the past year. The company is valued at $169 B. The stock sits at 80% of its 52-week range of $166–$252, +10.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 158 weeks in. — as of 17 September 2026.

What were Welltower Inc.'s latest quarterly results?

Welltower Inc. reported revenue of $3.5 B and net profit of $0.5 B for the Jun 26 quarter. Revenue rose 38.8% and profit rose 53.3% year on year. Earnings per share were $0.61. The operating margin was 14.1%, 3.2 pp lower than a year earlier. — as of 17 September 2026.

What is Welltower Inc.'s revenue?

Welltower Inc. reported revenue of $3.5 B in the Jun 26 quarter, +38.8% year on year. For the full FY25 fiscal year, revenue was $10.8 B (+35.7%). Over the last 4 years revenue compounded at 23.0% a year. — as of 17 September 2026.

What is Welltower Inc.'s profit?

Welltower Inc. earned $0.5 B of net profit in the Jun 26 quarter, +53.3% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $1.0 B. The operating margin ran 14.1% in the latest quarter. — as of 17 September 2026.

What is Welltower Inc.'s market cap?

Welltower Inc.'s market capitalisation is $169 B at a stock price of $235. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

What is Welltower Inc.'s P/E ratio?

Welltower Inc. trades at a P/E of 106.3×, at the 35th percentile of its own 5-year range, against a long-run median of 120.7×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.

Does Welltower Inc. pay a dividend?

Yes — Welltower Inc. declared $0.85 per share for Jun 26, and $3.07 per share across the last four reported quarters. — as of 17 September 2026.

What is Welltower Inc.'s dividend per share?

Welltower Inc.'s most recently declared dividend is $0.85 per share for Jun 26, giving $3.07 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.

What is Welltower Inc.'s dividend yield?

Welltower Inc.'s trailing dividend yield is 1.31%: $3.07 declared per share across the last four reported quarters, against a share price of $235. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.

Is Welltower Inc. overvalued?

On its own history, Welltower Inc. looks cheap: its P/E of 106.3× has been cheaper only 35% of the time in 5 years (long-run median 120.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.

Is Welltower Inc. growing?

Yes — Welltower Inc. is growing: latest-quarter revenue +38.8% year on year, profit +53.3%, and the margin −3.2 pp at 14.1%. The 4-year compound rates are 23.0% (revenue) and 26.9% (profit). The earnings engine currently reads: improving — as of 17 September 2026.

How is Welltower Inc. performing?

Welltower Inc. is in a confirmed uptrend, 158 weeks in. Its latest quarter's revenue rose 38.8% and profit rose 53.3% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 13 weeks. This describes what the data did, not a rating. — as of 17 September 2026.

What stage is Welltower Inc. in?

Mixed — the growth curves are steadily positive, but ROCE at 0.8% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +37.5% latest, profit growth +41.2% latest, eps growth +23.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.

Is Welltower Inc. in an uptrend?

Yes — the price is in a confirmed uptrend (week 158 of stage 2), trading +10.6% versus its 200-day average and at 80% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.

Is Welltower Inc. beating the market?

On recent form, yes — Welltower Inc. has been ahead of the S&P 500 on a trailing-13-week view for 13 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +210% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.

Will Welltower Inc.'s stock price go up?

This page publishes no price forecast for Welltower Inc. What it measures instead: the stock price is $235, the price is in a confirmed uptrend 158 weeks in. Its P/E of 106.3× sits at the 35th percentile of its own 5-year range. — as of 17 September 2026.

Is the market betting against Welltower Inc.?

Somewhat — short interest is 2.6% of Welltower Inc.'s tradable float, about 6.2 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.

Does Welltower Inc. have too much debt?

It is moderate — Welltower Inc.'s debt-to-equity is 0.41. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.

What is Welltower Inc.'s capex?

Welltower Inc. spent $5.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.5 B. — as of 17 September 2026.

What is Welltower Inc.'s cash flow?

Welltower Inc. generated $2.9 B of operating cash flow in FY25 and $1.4 B of free cash flow after $1.5 B of capital spending. Reported profit that year was $1.0 B, so operating cash ran ahead of profit. — as of 17 September 2026.

Is Welltower Inc.'s profit real cash?

Yes — over the last 3 fiscal years, 294% of Welltower Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $2.9 B against reported profit of $1.0 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.

Where is Welltower Inc. in its business cycle?

Welltower Inc.'s FY25 operating margin was 1.8%, against a 5-year band of 1.8%–14.8%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 14.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the Welltower Inc. story?

The sharpest disagreement: the price moved +42.0% in a year while annual EPS moved −11.5% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is Welltower Inc. a stock worth studying right now?

This is not investment advice. The machine read: Welltower Inc. is coiled. The quarters are improving, yet the P/E sits at the 35th percentile of its own 5-year range — the business is moving before the market. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI